Compare OFLX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFLX | CBIO |
|---|---|---|
| Founded | 1975 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.0M | 340.4M |
| IPO Year | 2005 | N/A |
| Metric | OFLX | CBIO |
|---|---|---|
| Price | $28.99 | $10.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 37.1K | ★ 147.9K |
| Earning Date | 06-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $98,296,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.58 | $8.72 |
| 52 Week High | $39.98 | $17.39 |
| Indicator | OFLX | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 30.83 | 40.20 |
| Support Level | $26.50 | $8.72 |
| Resistance Level | $29.54 | $13.36 |
| Average True Range (ATR) | 1.76 | 0.85 |
| MACD | -0.59 | -0.14 |
| Stochastic Oscillator | 16.07 | 8.21 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.